Skip to content
Home
Our Science
Therapeutic Areas
Team & Investors
Careers
News & Resources
Connect
News &
Resources
Featured Stories
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Read More
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Read More
Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
Read More
All-In Podcast
2023 All-In Summit – A discussion on the future of gene therapy
Read More
News
Patient Resources
Videos
All
Media Coverage
Press Releases
Media Coverage
|
Posted on 12.13.24
Siren CEO and Founder Dr. Nicole Paulk honored in Slice of Healthcare’s 50 Under 50 list
Read More
Media Coverage
|
Posted on 11.20.24
Siren Biotechnology awarded BioTech Breakthroughs Innovation of the Year Award
Read More
Media Coverage
|
Posted on 11.18.24
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Read More
Press Releases
|
Posted on 11.18.24
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Read More
Media Coverage
|
Posted on 10.11.24
Siren CEO & Founder Dr. Nicole Paulk honored as one of the Most Influential Women in Bay Area Business
Read More
Media Coverage
|
Posted on 9.17.24
AAV downstream challenges: expert insights
Read More
Media Coverage
|
Posted on 8.15.24
Siren Biotechnology Wins Beckman Coulter SPRI Grants for Genomic Research
Read More
Media Coverage
|
Posted on 8.9.24
Unveiling the critical pathways in AAV potency evaluation and future trends in gene therapy
Read More
Media Coverage
|
Posted on 7.26.24
BioBreakthroughs: Gene Therapy Innovation
Read More
Media Coverage
|
Posted on 6.28.24
Building A Universal AAV For Cancer
Read More
1
2
3
4
